NasdaqGS - Delayed Quote USD

DexCom, Inc. (DXCM)

124.34 -13.67 (-9.91%)
At close: April 26 at 4:00 PM EDT
124.38 +0.04 (+0.03%)
After hours: April 26 at 7:54 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
3,801,800.00
3,622,300.00
2,909,800.00
2,448,500.00
1,926,700.00
Cost of Revenue
1,413,600.00
1,333,400.00
1,026,700.00
768,000.00
646,600.00
Gross Profit
2,388,200.00
2,288,900.00
1,883,100.00
1,680,500.00
1,280,100.00
Operating Expense
1,736,600.00
1,691,200.00
1,491,900.00
1,414,700.00
980,600.00
Operating Income
651,600.00
597,700.00
391,200.00
265,800.00
299,500.00
Net Non Operating Interest Income Expense
128,700.00
114,700.00
5,200.00
-17,100.00
-68,600.00
Other Income Expense
-1,900.00
-2,000.00
-5,600.00
8,100.00
-5,900.00
Pretax Income
778,400.00
710,400.00
390,800.00
256,800.00
225,000.00
Tax Provision
139,100.00
168,900.00
49,600.00
39,900.00
-268,600.00
Net Income Common Stockholders
639,300.00
541,500.00
341,200.00
216,900.00
493,600.00
Average Dilution Earnings
13,900.00
12,600.00
11,000.00
11,400.00
--
Diluted NI Available to Com Stockholders
653,200.00
554,100.00
352,200.00
228,300.00
493,600.00
Basic EPS
1.65
1.40
0.88
0.56
1.31
Diluted EPS
1.54
1.30
0.82
0.53
1.26
Basic Average Shares
386,875.00
386,000.00
389,400.00
386,900.00
377,600.00
Diluted Average Shares
425,050.00
425,500.00
427,500.00
428,800.00
390,000.00
Total Operating Income as Reported
651,600.00
597,700.00
391,200.00
265,800.00
299,500.00
Total Expenses
3,150,200.00
3,024,600.00
2,518,600.00
2,182,700.00
1,627,200.00
Net Income from Continuing & Discontinued Operation
639,300.00
541,500.00
341,200.00
216,900.00
493,600.00
Normalized Income
639,300.00
541,500.00
341,200.00
216,960.10
497,907.00
Interest Income
149,000.00
135,000.00
23,800.00
1,700.00
16,100.00
Interest Expense
20,300.00
20,300.00
18,600.00
18,800.00
84,700.00
Net Interest Income
128,700.00
114,700.00
5,200.00
-17,100.00
-68,600.00
EBIT
798,700.00
730,700.00
409,400.00
275,600.00
309,700.00
EBITDA
995,600.00
916,700.00
565,300.00
377,600.00
376,800.00
Reconciled Cost of Revenue
1,413,600.00
1,333,400.00
1,026,700.00
768,000.00
646,600.00
Reconciled Depreciation
196,900.00
186,000.00
155,900.00
102,000.00
67,100.00
Net Income from Continuing Operation Net Minority Interest
639,300.00
541,500.00
341,200.00
216,900.00
493,600.00
Total Unusual Items Excluding Goodwill
--
--
--
-100.00
-5,900.00
Total Unusual Items
--
--
--
-100.00
-5,900.00
Normalized EBITDA
995,600.00
916,700.00
565,300.00
377,700.00
382,700.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
--
-39.90
-1,593.00
12/31/2020 - 4/14/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALGN Align Technology, Inc.
309.02
-0.48%
 
BSX Boston Scientific Corporation
73.17
-0.12%
 
EW Edwards Lifesciences Corporation
86.43
-1.80%
 
PODD Insulet Corporation
166.19
+1.23%
 
TNDM Tandem Diabetes Care, Inc.
35.24
-0.90%
 
ABT Abbott Laboratories
107.53
+0.63%
 
SYK Stryker Corporation
335.61
-0.46%
 
MDT Medtronic plc
79.74
+0.62%
 
TMDX TransMedics Group, Inc.
92.08
+3.17%
 
SENS Senseonics Holdings, Inc.
0.4157
-0.60%